Protara Therapeutics, Inc.
About Protara Therapeutics, Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2014
- $2.9M
- Net income
- -$57.4M
- Total assets
- $209.5M
- Market cap
- $233.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $64.5M
- Operating income
- -$64.5M
- Income tax
- -$11.0M
- Net income
- -$57.4M
- EPS (basic)
- $-1.34
- EPS (diluted)
- $-1.34
Balance sheet
- Total assets
- $209.5M
- Current assets
- $159.5M
- Total liabilities
- $13.1M
- Current liabilities
- $10.9M
- Shareholders’ equity
- $196.4M
Cash flow
- Operating cash flow
- -$56.4M
- Investing cash flow
- -$139.5M
- Financing cash flow
- $82.7M
- Net cash flow
- -$113.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $233.8M
- EPS (diluted)
- $-1.34
- Shares outstanding
- 61.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 10, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $57.4M in FY2014.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Protara Therapeutics, Inc..
Write a review
News about Protara Therapeutics, Inc.
News & sentiment via Polygon.io
